Molecular and biological factors in the prognosis of non-small cell lung cancer.

For patients with non-small cell lung cancer the tumour/node/metastasis (TNM) staging system and other conventional prognostic factors fail to predict the outcome of treatment and survival accurately. New prognostic factors are urgently needed to improve understanding of the biological behaviour of the different subtypes of non-small cell lung cancer and to recognize patients with a good or poor prognosis. This review will focus on molecular and biological factors published in the English language literature between 1988 and 1994. To be included in this survey, the predictive value of a specific prognostic factor had to be confirmed by multivariate analysis in at least two different studies. Blood group antigen expression, ras oncogenes, microvessel density, and factors reflecting the proliferative state of the tumour may be important determinants of outcome of treatment. The search for new determinants of prognosis has provided insight in the complex tumour biology of non-small cell lung cancer and indicated possible targets for tumour therapy. Several promising prognostic factors have now been recognized. To validate these factors, prospective studies of a large patient population are needed. This ultimately serves the recognition of subsets of patients who may benefit from adjuvant therapy.

[1]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[2]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[3]  P. Zimmerman,et al.  PLOIDY AS A PROGNOSTIC DETERMINANT IN SURGICALLY TREATED LUNG CANCER , 1987, The Lancet.

[4]  D. Stacey,et al.  Cellular ras activity and tumor cell proliferation. , 1987, Experimental cell research.

[5]  K. Sugimachi,et al.  Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. , 1993, Cancer research.

[6]  I. Taylor,et al.  Clinical and biological significance of aneuploidy in human tumours. , 1984, Journal of clinical pathology.

[7]  A. Harris,et al.  bcl-2 protein in non-small-cell lung carcinoma. , 1993, The New England journal of medicine.

[8]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[9]  S. Rodenhuis,et al.  C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. , 1994, The Journal of clinical investigation.

[10]  S. Rodenhuis,et al.  Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. , 1987, The New England journal of medicine.

[11]  M. Boon,et al.  The prognostic significance of morphometry in T1 bladder tumours , 1981, Histopathology.

[12]  P. Demoly,et al.  Neural cell adhesion molecule and prognosis of surgically resected lung cancer. , 1993, The American review of respiratory disease.

[13]  F. McCormick,et al.  Regulators and effectors of ras proteins. , 1991, Annual review of cell biology.

[14]  A. Sahin,et al.  Flow cytometric analysis of the DNA content of non‐small cell lung cancer ploidy as a significant prognostic indicator in squamous cell carcinoma of the lung , 1990, Cancer.

[15]  J. Mate,et al.  Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. , 1993, Oncogene.

[16]  V. Roggli,et al.  Absence of correlation between nuclear morphometry and survival in stage I non‐small cell lung carcinoma , 1992, Cancer.

[17]  R. Ueda,et al.  p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. , 1992, Cancer research.

[18]  D. Weiner,et al.  p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.

[19]  B. Eisenstein,et al.  The polymerase chain reaction. A new method of using molecular genetics for medical diagnosis. , 1990, The New England journal of medicine.

[20]  R A Laskey,et al.  S phase of the cell cycle. , 1989, Science.

[21]  D. Taub,et al.  Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. , 1993, Journal of the National Cancer Institute.

[22]  S. Capewell,et al.  Performance and prognosis in patients with lung cancer. The Edinburgh Lung Cancer Group. , 1990, Thorax.

[23]  O. Dalesio,et al.  Neural cell adhesion molecule expression, neuroendocrine differentiation and prognosis in lung carcinoma. , 1991, European journal of cancer.

[24]  M. Melamed,et al.  The effect of tumor size and tumor cell DNA content on the survival of patients with stage I adenocarcinoma of the lung , 1989, Cancer.

[25]  R L Smith,et al.  Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. , 1993, Science.

[26]  A. Sahin,et al.  Expression of blood-group antigen A--a favorable prognostic factor in non-small-cell lung cancer. , 1991, The New England journal of medicine.

[27]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[28]  M. Boon,et al.  Prognostic indicators in breast cancer‐morphometric methods , 1982, Histopathology.

[29]  S. Wagenaar,et al.  The percentage of aneuploid cells is significantly correlated with survival in accurately staged patients with stage 1 resected squamous cell lung cancer and long‐term follow up , 1989, Cancer.

[30]  A. Hall,et al.  The cellular functions of small GTP-binding proteins. , 1990, Science.

[31]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[32]  J. Baak,et al.  Evaluation of prognostic characteristics of stage I cutaneous malignant melanoma. , 1984, Analytical and quantitative cytology.

[33]  J. Minna,et al.  Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Lung Cancer Study Group. , 1990, Oncogene.

[34]  K. Sugimachi,et al.  ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. , 1992, Cancer research.

[35]  Y. Nakamura,et al.  Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma and adenocarcinoma of the lung. , 1992, Cancer research.

[36]  W. McGuire,et al.  Flow cytometry, cellular DNA content, and prognosis in human malignancy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  C. Angeletti,et al.  Most peripheral, node-negative, non-small-cell lung cancers have low proliferative rates and no intratumoral and peritumoral blood and lymphatic vessel invasion. Rationale for treatment with wedge resection alone. , 1992, The Journal of thoracic and cardiovascular surgery.

[38]  H. Asamura,et al.  Nuclear DNA content by cytofluorometry of stage I adenocarcinoma of the lung in relation to postoperative recurrence. , 1989, Chest.

[39]  R. Ueda,et al.  Three distinct regions involved in 3p deletion in human lung cancer. , 1992, Oncogene.

[40]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[41]  K. Suemasu,et al.  Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 CM in diameter , 1988, Cancer.

[42]  C. Angeletti,et al.  Relation of neovascularisation to metastasis of non-small-cell lung cancer , 1992, The Lancet.

[43]  K. Sugimachi,et al.  Nucleolar organizer regions as a prognostic indicator for stage I non-small cell lung cancer. , 1991, Cancer research.

[44]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[45]  H. Dosaka-akita,et al.  Prognostic significance of the expression of ras oncogene product in non‐small cell lung cancer , 1992, Cancer.

[46]  A. Srivastava,et al.  The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study. , 1988, The American journal of pathology.

[47]  S. Hakomori,et al.  Blood Group Antigens , 1974 .

[48]  C. Mountain.  The new International Staging System for Lung Cancer. , 1986, The Surgical clinics of North America.

[49]  G. Fontanini,et al.  Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. , 1994, The Annals of thoracic surgery.

[50]  R. Tsuchiya,et al.  Prognosis and survival in resected lung carcinoma based on the new international staging system. , 1988, The Journal of thoracic and cardiovascular surgery.

[51]  Judah Folkman,et al.  Angiogenesis in vitro , 1980, Nature.

[52]  D. Lane,et al.  The relationship of p53 immunostaining to survival in carcinoma of the lung. , 1992, British Journal of Cancer.

[53]  R. Dodge,et al.  Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. , 1993, Archives of surgery.

[54]  H Stein,et al.  Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. , 1984, Journal of immunology.

[55]  J. Pujol,et al.  In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. , 1990, Cancer research.

[56]  S. Hakomori,et al.  A specific cell surface glycoconjugate controlling cell motility: evidence by functional monoclonal antibodies that inhibit cell motility and tumor cell metastasis. , 1991, Biochemistry.

[57]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[58]  S. Hakomori,et al.  Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. , 1989, Advances in cancer research.

[59]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[60]  T Takahashi,et al.  Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. , 1993, Cancer research.

[61]  S. Korsmeyer,et al.  BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Yoshida,et al.  Intracellular localization and metabolism of DNA polymerase alpha in human cells visualized with monoclonal antibody. , 1984, Experimental cell research.

[63]  S. Rodenhuis,et al.  Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. , 1988, Cancer research.

[64]  C. Angeletti,et al.  The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node‐negative non‐small cell lung cancer , 1992, Cancer.

[65]  H. Dvorak,et al.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.

[66]  P. Hasleton,et al.  Vascular invasion in non-small cell lung carcinoma. , 1992, Journal of clinical pathology.

[67]  S. Hakomori,et al.  Correlation of expression of H/Le(y)/Le(b) antigens with survival in patients with carcinoma of the lung. , 1992, The New England journal of medicine.

[68]  K. Inoue,et al.  Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non‐small cell lung cancer , 1990, Cancer.

[69]  G. Silvestri,et al.  Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. , 1992, The American review of respiratory disease.

[70]  S. Steinberg,et al.  Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. , 1994, Cancer research.

[71]  J. Bos,et al.  The ras gene family and human carcinogenesis. , 1988, Mutation research.

[72]  S. Wagenaar,et al.  Monoclonal antibody 123C3 in lung tumour classification. Immunohistology of 358 resected lung tumours. , 1988, Molecular and cellular probes.

[73]  J. Minna,et al.  Amplification and expression of the c-myc oncogene in human lung cancer cell lines , 1983, Nature.

[74]  J. Baak,et al.  Nuclear morphometry as an important prognostic factor in stage I renal cell carcinoma , 1986, Cancer.

[75]  J. Mortimer,et al.  The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.